Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

Lorenzo Moja; Ersilia Lucenteforte; Koren H Kwag; Vittorio Bertele; Annalisa Campomori; Usha Chakravarthy; Roberto D'Amico; Kay Dickersin; Laurent Kodjikian; Kristina Lindsley; Yoon Loke; Maureen Maguire; Daniel F Martin; Alessandro Mugelli; Bernd Mühlbauer; Isabel Püntmann; Barnaby Reeves; Chris Rogers; Christine Schmucker; Manju L Subramanian; Gianni Virgili

doi:10.1002/14651858.CD011230.pub2

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

Lorenzo Moja
, Ersilia Lucenteforte
, Koren H Kwag
, Vittorio Bertele
, Annalisa Campomori
, Usha Chakravarthy
, Roberto D'Amico
, Kay Dickersin
, Laurent Kodjikian
, Kristina Lindsley
, Yoon Loke
, Maureen Maguire
, Daniel F Martin
, Alessandro Mugelli
, Bernd Mühlbauer
, Isabel Püntmann
, Barnaby Reeves
, Chris Rogers
, Christine Schmucker
, Manju L Subramanian

Gianni Virgili

Research output: Contribution to journal › Article › peer-review

191 Citations (Scopus)

Abstract

Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in elderly populations of industrialised countries. Bevacizumab (Avastin®) and ranibizumab (Lucentis®) are targeted biological drugs (a monoclonal antibody) that inhibit vascular endothelial growth factor, an angiogenic cytokine that promotes vascular leakage and growth, thereby preventing its pathological angiogenesis. Ranibizumab is approved for intravitreal use to treat neovascular AMD, while bevacizumab is approved for intravenous use as a cancer therapy. However, due to the biological similarity of the two drugs, bevacizumab is widely used off-label to treat neovascular AMD.

Original language	English
Article number	CD011230
Journal	Cochrane Database of Systematic Reviews
Volume	9
Early online date	15 Sept 2014
DOIs	https://doi.org/10.1002/14651858.CD011230.pub2
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1002/14651858.CD011230.pub2

Cite this

Moja, L., Lucenteforte, E., Kwag, K. H., Bertele, V., Campomori, A., Chakravarthy, U., D'Amico, R., Dickersin, K., Kodjikian, L., Lindsley, K., Loke, Y., Maguire, M., Martin, D. F., Mugelli, A., Mühlbauer, B., Püntmann, I., Reeves, B., Rogers, C., Schmucker, C., ... Virgili, G. (2014). Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews, 9, Article CD011230. https://doi.org/10.1002/14651858.CD011230.pub2

@article{c4dea91b33664c55826be690fe6034c6,

title = "Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration",

abstract = "Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in elderly populations of industrialised countries. Bevacizumab (Avastin{\textregistered}) and ranibizumab (Lucentis{\textregistered}) are targeted biological drugs (a monoclonal antibody) that inhibit vascular endothelial growth factor, an angiogenic cytokine that promotes vascular leakage and growth, thereby preventing its pathological angiogenesis. Ranibizumab is approved for intravitreal use to treat neovascular AMD, while bevacizumab is approved for intravenous use as a cancer therapy. However, due to the biological similarity of the two drugs, bevacizumab is widely used off-label to treat neovascular AMD.",

author = "Lorenzo Moja and Ersilia Lucenteforte and Kwag, \{Koren H\} and Vittorio Bertele and Annalisa Campomori and Usha Chakravarthy and Roberto D'Amico and Kay Dickersin and Laurent Kodjikian and Kristina Lindsley and Yoon Loke and Maureen Maguire and Martin, \{Daniel F\} and Alessandro Mugelli and Bernd M{\"u}hlbauer and Isabel P{\"u}ntmann and Barnaby Reeves and Chris Rogers and Christine Schmucker and Subramanian, \{Manju L\} and Gianni Virgili",

year = "2014",

doi = "10.1002/14651858.CD011230.pub2",

language = "English",

volume = "9",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "Wiley",

}

Moja, L, Lucenteforte, E, Kwag, KH, Bertele, V, Campomori, A, Chakravarthy, U, D'Amico, R, Dickersin, K, Kodjikian, L, Lindsley, K, Loke, Y, Maguire, M, Martin, DF, Mugelli, A, Mühlbauer, B, Püntmann, I, Reeves, B, Rogers, C, Schmucker, C, Subramanian, ML & Virgili, G 2014, 'Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration', Cochrane Database of Systematic Reviews, vol. 9, CD011230. https://doi.org/10.1002/14651858.CD011230.pub2

TY - JOUR

T1 - Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

AU - Moja, Lorenzo

AU - Lucenteforte, Ersilia

AU - Kwag, Koren H

AU - Bertele, Vittorio

AU - Campomori, Annalisa

AU - Chakravarthy, Usha

AU - D'Amico, Roberto

AU - Dickersin, Kay

AU - Kodjikian, Laurent

AU - Lindsley, Kristina

AU - Loke, Yoon

AU - Maguire, Maureen

AU - Martin, Daniel F

AU - Mugelli, Alessandro

AU - Mühlbauer, Bernd

AU - Püntmann, Isabel

AU - Reeves, Barnaby

AU - Rogers, Chris

AU - Schmucker, Christine

AU - Subramanian, Manju L

AU - Virgili, Gianni

PY - 2014

Y1 - 2014

N2 - Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in elderly populations of industrialised countries. Bevacizumab (Avastin®) and ranibizumab (Lucentis®) are targeted biological drugs (a monoclonal antibody) that inhibit vascular endothelial growth factor, an angiogenic cytokine that promotes vascular leakage and growth, thereby preventing its pathological angiogenesis. Ranibizumab is approved for intravitreal use to treat neovascular AMD, while bevacizumab is approved for intravenous use as a cancer therapy. However, due to the biological similarity of the two drugs, bevacizumab is widely used off-label to treat neovascular AMD.

AB - Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in elderly populations of industrialised countries. Bevacizumab (Avastin®) and ranibizumab (Lucentis®) are targeted biological drugs (a monoclonal antibody) that inhibit vascular endothelial growth factor, an angiogenic cytokine that promotes vascular leakage and growth, thereby preventing its pathological angiogenesis. Ranibizumab is approved for intravitreal use to treat neovascular AMD, while bevacizumab is approved for intravenous use as a cancer therapy. However, due to the biological similarity of the two drugs, bevacizumab is widely used off-label to treat neovascular AMD.

U2 - 10.1002/14651858.CD011230.pub2

DO - 10.1002/14651858.CD011230.pub2

M3 - Article

C2 - 25220133

SN - 1465-1858

VL - 9

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

M1 - CD011230

ER -